ArticleNature communications2026
Engineered polymerase-mediated efficient synthesis of site-specifically functionalized RNA and 2'-modified RNA oligonucleotides via genetic alphabet expansion.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
2'-Modified RNA oligonucleotides have found broad use in biotechnology and biomedicine, requiring their efficient synthesis and controllable labelling. While engineered polymerases enable their synthesis, controllable labelling methods remain underdeveloped. Unnatural base pairs (UBPs) have been developed to expand the genetic alphabet, leading to not only the creation of semi-synthetic organisms, but also technologies for site-specific labelling of DNA and RNA. Herein we demonstrate that SFM4-6, an engineered polymerase optimized for 2'-modified RNA oligonucleotide synthesis, can efficiently synthesize unnatural base pair dNaM (2-methoxy-3-(2'-deoxy-β-D-erythro-pentofuranosyl)-naphthalene)-dTPT3 ((2'-deoxy-β-D-erythro-pentofuranosyl)-thieno[3,4]pyridine-2-thione) and its analogues, enabling site-specific incorporation of functionalized unnatural base-containing nucleotides into RNA and 2'-modified RNA oligonucleotides. By combining this with a strategy involving controlled pause and restart of primer extension, we establish methods for producing single or dual-labelled RNA and 2'-modified RNA oligonucleotides. These methods successfully produce various functional labelled RNA and 2'-modified RNA oligonucleotides, highlighting their broad applicability in nucleic acid research and biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.